Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francis J Giles

Showing results (1-10 of 339) with videos related to

Pageof 34
Sort By:
Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis|November 9, 2002
Leukapheresis in patients with previously untreated acute myeloid leukemiaFrancis J Giles
Expert Review of Anticancer Therapy|July 13, 2002
Troxacitabine-based therapy of refractory leukemiaFrancis J Giles
Current Drug Targets|July 23, 2011
Cancer--an increasingly target rich environmentFrancis J Giles
Current Opinion in Oncology|January 16, 2002
Novel agents for the therapy of acute leukemiaFrancis J Giles
Leukemia Research|April 10, 2007
A new era for ribonucleoside reductase inhibitionFrancis J Giles
Current Molecular Medicine|November 25, 2005
Targeted therapy in hematologic maligancies--progress made, lessons learned?Francis J Giles
Leukemia Research|April 25, 2006
FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targetingFrancis J Giles
Oncology (Williston Park, N.Y.)|July 10, 2002
The emerging role of angiogenesis inhibitors in hematologic malignanciesFrancis J Giles
Leukemia & Lymphoma|June 20, 2007
Bendamustine and cloretazine: alkylators with sharply contrasting activity in AMLFrancis J Giles
Seminars in Hematology|July 23, 2009
New directions in the treatment of imatinib failure and/or resistanceFrancis J Giles
Pageof 34

Showing results (1-10 of 339) with videos related to

Sort By:
Pageof 34
Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis|November 9, 2002
Leukapheresis in patients with previously untreated acute myeloid leukemiaFrancis J Giles
Expert Review of Anticancer Therapy|July 13, 2002
Troxacitabine-based therapy of refractory leukemiaFrancis J Giles
Current Drug Targets|July 23, 2011
Cancer--an increasingly target rich environmentFrancis J Giles
Current Opinion in Oncology|January 16, 2002
Novel agents for the therapy of acute leukemiaFrancis J Giles
Leukemia Research|April 10, 2007
A new era for ribonucleoside reductase inhibitionFrancis J Giles
Current Molecular Medicine|November 25, 2005
Targeted therapy in hematologic maligancies--progress made, lessons learned?Francis J Giles
Leukemia Research|April 25, 2006
FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targetingFrancis J Giles
Oncology (Williston Park, N.Y.)|July 10, 2002
The emerging role of angiogenesis inhibitors in hematologic malignanciesFrancis J Giles
Leukemia & Lymphoma|June 20, 2007
Bendamustine and cloretazine: alkylators with sharply contrasting activity in AMLFrancis J Giles
Seminars in Hematology|July 23, 2009
New directions in the treatment of imatinib failure and/or resistanceFrancis J Giles
Pageof 34